[go: up one dir, main page]

WO2011009059A3 - Method of treating or preventing cancer - Google Patents

Method of treating or preventing cancer Download PDF

Info

Publication number
WO2011009059A3
WO2011009059A3 PCT/US2010/042306 US2010042306W WO2011009059A3 WO 2011009059 A3 WO2011009059 A3 WO 2011009059A3 US 2010042306 W US2010042306 W US 2010042306W WO 2011009059 A3 WO2011009059 A3 WO 2011009059A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treating
preventing
inhibiting
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/042306
Other languages
French (fr)
Other versions
WO2011009059A2 (en
Inventor
Phillip A. Dennis
M. Christine Hollander
Marc Nicklaus
Megan Peach
Sherry R. Chemler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
US Department of Health and Human Services
Original Assignee
Research Foundation of the State University of New York
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York, US Department of Health and Human Services filed Critical Research Foundation of the State University of New York
Publication of WO2011009059A2 publication Critical patent/WO2011009059A2/en
Publication of WO2011009059A3 publication Critical patent/WO2011009059A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a method for inhibiting Akt, activating AMPK, inhibiting mTOR, treating or preventing development of cancer, and/or preventing progression of premalignant lesions to cancer in an animal comprising administering to the animal an effective amount of a compound as described herein, for example, NSC 743411, whose formula is set forth below. The method involves the use of these compounds as single agents or in combination with conventional chemotherapy, biological therapy, or radiation therapy. The invention further provides novel compounds and pharmaceutical compositions for use in treating or preventing development of cancer or preventing the progression of premalignant lesions into cancer. Also disclosed is a method of inhibiting CSF1R.
PCT/US2010/042306 2009-07-17 2010-07-16 Method of treating or preventing cancer Ceased WO2011009059A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22632809P 2009-07-17 2009-07-17
US61/226,328 2009-07-17

Publications (2)

Publication Number Publication Date
WO2011009059A2 WO2011009059A2 (en) 2011-01-20
WO2011009059A3 true WO2011009059A3 (en) 2011-04-21

Family

ID=42668073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042306 Ceased WO2011009059A2 (en) 2009-07-17 2010-07-16 Method of treating or preventing cancer

Country Status (1)

Country Link
WO (1) WO2011009059A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI849808B (en) 2022-03-18 2024-07-21 共信醫藥科技股份有限公司 Use of pharmaceutical composition and chemotherapy agent in the manufacture of medicament for treating cancer
CN115073495B (en) * 2022-08-09 2024-03-19 苏州大学 An indoline compound and its preparation method

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
US5116874A (en) * 1985-09-23 1992-05-26 Eli Lilly And Company Anti-tumor method and compounds
EP0550157A1 (en) * 1991-12-20 1993-07-07 Eli Lilly And Company Antitumor compositions and methods of treatment
EP0602878A1 (en) * 1992-12-10 1994-06-22 Eli Lilly And Company Diarylsulfonylureas and their use as antitumor agents
WO2005040101A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates
EP1859797A1 (en) * 2005-02-28 2007-11-28 Eisai R&D Management Co., Ltd. Novel concomitant use of sulfonamide compound with anti-cancer agent
WO2010005534A2 (en) * 2008-06-30 2010-01-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome inhibitors for selectively inducing apoptosis in cancer cells
WO2010129596A1 (en) * 2009-05-04 2010-11-11 Agios Pharmaceuticals, Inc. Pmk2 modulators for use in the treatment of cancer
WO2010130665A1 (en) * 2009-05-12 2010-11-18 F. Hoffmann-La Roche Ag Azacyclic spiroderivatives as hsl inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
US5116874A (en) * 1985-09-23 1992-05-26 Eli Lilly And Company Anti-tumor method and compounds
EP0550157A1 (en) * 1991-12-20 1993-07-07 Eli Lilly And Company Antitumor compositions and methods of treatment
EP0602878A1 (en) * 1992-12-10 1994-06-22 Eli Lilly And Company Diarylsulfonylureas and their use as antitumor agents
WO2005040101A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates
EP1859797A1 (en) * 2005-02-28 2007-11-28 Eisai R&D Management Co., Ltd. Novel concomitant use of sulfonamide compound with anti-cancer agent
WO2010005534A2 (en) * 2008-06-30 2010-01-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome inhibitors for selectively inducing apoptosis in cancer cells
WO2010129596A1 (en) * 2009-05-04 2010-11-11 Agios Pharmaceuticals, Inc. Pmk2 modulators for use in the treatment of cancer
WO2010130665A1 (en) * 2009-05-12 2010-11-18 F. Hoffmann-La Roche Ag Azacyclic spiroderivatives as hsl inhibitors

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
AVDEENKO A P ET AL: "Thiocyanation of N-Arylsulfonyl-, N-Aroyl-, and N-(N-Arylsulfonyl)benzimidoyl)-1,4-benzoquinone Iminies", RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, CONSULTANTS BUREAU, US, vol. 45, no. 3, 29 April 2009 (2009-04-29), pages 408 - 416, XP002586945, ISSN: 1070-4280 *
BAXTER I ET AL: "Preparation and some reactions of 6-arylsulphonimidobenzoxazol-2(3H)-one", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY, CHEMICAL SOCIETY. LETCHWORTH, GB, 1 January 1970 (1970-01-01), pages 850 - 853, XP008122990, ISSN: 0022-4952, DOI: DOI:10.1039/J39700000850 *
COLLINS I ET AL: "Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 4, 15 February 2006 (2006-02-15), pages 1255 - 1273, XP025133010, ISSN: 0968-0896, [retrieved on 20060215], DOI: DOI:10.1016/J.BMC.2005.09.055 *
D. A. GUERTIN, D. M. SABATINI: "Defining the role of mTOR in cancer", CANCER CELL, vol. 12, July 2007 (2007-07-01), pages 9 - 22, XP002599504 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 April 2005 (2005-04-15), "Benzoic acid, 4-(1-piperidinylsulfonyl)-, 2-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-2-oxoethyl ester", XP002599503, retrieved from STN accession no. RN 848580-83-6 *
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 30 December 2004 (2004-12-30), "Benzoic acid, 3-[(2,3-dihydro-1H-indol-1-yl)sulfonyl], 2-[(3-cyano-2-thienyl)amino]-2-oxoethyl ester", XP002599502, retrieved from STN accession no. RN 805306-56-3 *
DATABASE ZREGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 28 July 2005 (2005-07-28), ""Acetic acid, 2-[[4-[[(4-ethoxyphenyl)sulfonyl]imino]-1,4-dihydro-1-oxo-2-naphthalenyl]thio]-"", XP002615085, retrieved from STN accession no. RN 857494-31-6 *
FAIVRE S ET AL: "Current development of mTOR inhibitors as anticancer agents", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB LNKD- DOI:10.1038/NRD2062, vol. 5, no. 8, 1 August 2006 (2006-08-01), pages 671 - 688, XP002587702, ISSN: 1474-1784 *
FUJITA, S. AND SANO K.: "reduction of quinones and quinonemonosulfonimides with N,N-diethylhydroxylamine", JOURNAL OF ORGANIC CHEMISTRY, vol. 44, no. 5, 1979, pages 2647 - 2649, XP007916530 *
HAYAKAWA ET AL: "Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 17, 19 July 2007 (2007-07-19), pages 5837 - 5844, XP022152373, ISSN: 0968-0896, DOI: DOI:10.1016/J.BMC.2007.05.070 *
LIU Q ET AL: "MTOR mediated anti-cancer drug discovery", DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES 2009 ELSEVIER LTD GBR LNKD- DOI:10.1016/J.DDSTR.2009.12.001, vol. 6, no. 2, December 2009 (2009-12-01), pages 47 - 55, XP027103036, ISSN: 1740-6773 *
MORGENSZTERN D ET AL: "PI3K/Akt/mTOR pathway as a target for cancer therapy", ANTI-CANCER DRUGS, LIPPINCOTT WILLIAMS & WILKINS, US; NL LNKD- DOI:10.1097/01.CAD.0000173476.67239.3B, vol. 16, no. 8, 1 January 2005 (2005-01-01), pages 797 - 803, XP008092039, ISSN: 0959-4973 *
PIAO WENHUA ET AL: "Induction of G2/M phase arrest and apoptosis by a new synthetic anti-cancer agent, DW2282, in promyelocytic leukemia (HL-60) cells", BIOCHEMICAL PHARMACOLOGY, vol. 62, no. 11, 1 December 2001 (2001-12-01), pages 1439 - 1447, XP007916529, ISSN: 0006-2952 *
SHERMAN E S ET AL: "Pyrrolidine and piperidine formation via copper(II) carboxylate-promoted intramolecular carboamination of unactivated olefins: Diastereoselectivity and mechanism", JOURNAL OF ORGANIC CHEMISTRY 20070511 AMERICAN CHEMICAL SOCIETY US, vol. 72, no. 10, 11 May 2007 (2007-05-11), pages 3896 - 3905, XP002615086, DOI: DOI:10.1021/JO070321U *
SUN E ET AL: "Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984)", BIOCHEMICAL PHARMACOLOGY 1995 US LNKD- DOI:10.1016/0006-2952(95)02050-0, vol. 50, no. 9, 1995, pages 1461 - 1468, XP007916528, ISSN: 0006-2952 *

Also Published As

Publication number Publication date
WO2011009059A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
JO2848B1 (en) Organic Compounds
MY155961A (en) Chemical compounds 251
BR112012009215A2 (en) "cancer combined therapy with hsp90 inhibitor compounds"
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
JO3265B1 (en) Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
MX2009008439A (en) Novel inhibitors hepatitis c virus replication.
MX2009006742A (en) Novel compounds.
NZ619259A (en) Inhibitors of influenza viruses replication
TW200833663A (en) Therapeutic agents
WO2012083122A8 (en) Inhibitors of influenza viruses replication
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
TNSN07419A1 (en) Methods for treating drug resistant cancer
MX2009006764A (en) Bicyclic pyrimidinones and uses thereof.
MX2010001020A (en) Organic compounds.
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
MX2011009709A (en) Compounds for treating inflammation and pain.
ATE522500T1 (en) AMIDE DERIVATIVES AS ION CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
NZ592429A (en) PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
MX2008016358A (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors.
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
MX2009013482A (en) [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10737173

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10737173

Country of ref document: EP

Kind code of ref document: A2